Institute Of Oncology Ljubljana — Clinical Trial Site

16 Registered trials

6 Currently recruiting

Organisation

Institute Of Oncology Ljubljana

Location

Ljubljana, Slovenia

Identifier

ORG-100046044

Address

Zaloska Cesta 2, 1000, Slovenia

Departments

6801: Oncology
6871: Division of Medical Oncology
Department of Medical Oncology
Department of Radiotherapy
Department of Surgical Oncology
Division of Medical Oncology
Institute of Oncology
Medical Oncology
Radiation Oncology
Radiotherapy
Sektor internistične onkologije
Surgery

Clinical trials at this site (16)

Search interface

CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Not authorised

2023-506019-16-01 TRIPLE NEGATIVE BREAST CANCER 7
EORTC 2237-BCG-QLG: Improvement of Quality of Life through supportive treatments for Endocrine Therapy – related symptoms in patients with e… Not authorised

2024-513442-10-00 ER positive HER2 negative breast cancer stages I-II 5
CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Pending

2023-506019-16-03 TRIPLE NEGATIVE BREAST CANCER 7
Effect of perioperative intravenous infusion of lidocaine on the postoperative course and the immune response in patients undergoing surgery… Pending

2025-521808-22-01 Colon cancer 4
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Melanoma 5 2025-12-19
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formu… Recruiting

2023-510017-26-00 Completely Resected Stage IIB, IIC, and III Melanoma 1 2024-10-02
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted

2023-510082-10-00 Advanced non-small cell lung cancer harboring the KRAS 5 2022-09-05
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended

2022-502339-20-00 Squamous cell carcinoma of head and neck 4 2023-11-15
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non−Small Cell Lung Cancer who have already received chemo… Ended

2023-503756-27-00 Non-Small Cell Lung Cancer (NSCLC) 4 2022-03-31
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af… Ended

2023-509137-39-00 Stage IB (T ≥ 4 cm), II and IIIA NSCLC 5 2015-11-06